Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2017 / Articles / Sep / The Formulation Complex
Business & Regulation Formulation Drug Delivery Ingredients Dosage Forms Drug Delivery

The Formulation Complex

Unravelling the challenges and trends in formulation best practice – and why lipids and softgels are leading the way.

09/20/2017 1 min read

Share

In this special sponsored supplement, experts from BASF, Catalent and the University of Saskatchewan share their insight and experiences with developing lipid-based drug delivery systems. They offer their tips and advice on overcoming the most common formulation mishaps and why beginning with the end in mind is crucial.

>> Download the PDF here.
or read individual articles by following the links below:

Complexity and Collaboration

Leading the Way with Lipids

Formulation Best Practice

Formulating the Future

Today’s patients and payers are demanding – they want the most effective medicines, in a convenient format, at a cost effective price, and there is huge pressure on pharma companies and formulators to get it right. On one hand, there is much criticism of the drug industry, but on the other there is also much confidence that the industry and its scientists have the ability to deliver. And why shouldn’t they? There are more drug development technologies than ever before to help with the task, including sophisticated modelling techniques to help with the selection process, and an ever-expanding number of contract development and manufacturing organizations (CDMOs) and other experts dedicated to formulation and drug delivery. Solubility, bioavailability and permeability, however, continue to pose significant obstacles in development. Many formulators reading this will no doubt have come across a molecule at some point in their career that was impossible to get absorbed into the human body in the right amounts. The simple truth is that development is difficult – every molecule is unique and there is no one-size-fits-all formulation panacea that will produce an optimal drug every time. Ironically, formulators are victims of their own achievements – with more approaches to tackle previously unviable drugs, and many success stories, companies are more confident that solubility and other issues can be overcome with clever thinking, meaning that more and more challenging molecules are filling development pipelines. Formulation is also challenging from a time and cost perspective. In all sectors of the industry, people are being asked to do more with less, and the temptation for a scientist to quickly look to a previously successful formulation technology he or she has used in the past, rather than evaluating all available options in the toolbox, is high. One approach that can be overlooked are lipid based drug delivery systems (LBDDS), which can be tricky to get right but are highly effective at solubilizing hydrophobic compounds. LBDDS are already influencing commercial success stories and are expected to be a prominent tool in the future, particularly given their potential to assist with the oral delivery of biopharmaceuticals. The complex task of formulation does not need to be tackled by just one person or one team; collaborating with research organizations, other companies, CDMOs and suppliers makes sense. This supplement embodies the spirit of collaboration – jointly sponsored by BASF and Catalent, who collaborate to develop high-quality formulation options. In the following pages, experts discuss the challenges facing formulators today, the importance of excipients, and best practice tips for formulation with LBDDS.

>> Download the PDF here.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

Related Content

What About the Kids?
Formulation
What About the Kids?

December 3, 2014

0 min read

Since the late 1990s, new regulations have given us the opportunity to address the needs of the most vulnerable and demanding patients – children...

Squid-Inspired Drug Delivery
Drug Delivery Dosage Forms Formulation
Squid-Inspired Drug Delivery

April 3, 2025

4 min read

Here’s how researchers took lessons from cephalopods to develop a new capsule that can deliver drugs, including insulin and siRNA, orally

Schizophrenia and the Future of Long-Acting Therapeutics
Formulation Dosage Forms Drug Delivery
Schizophrenia and the Future of Long-Acting Therapeutics

March 11, 2025

5 min read

Long-acting injectables help with adherence, but what if an unfolding pill could provide an oral option?

The Power of Industry and Academic Collaboration
Drug Discovery Formulation
The Power of Industry and Academic Collaboration

March 13, 2025

6 min read

Purdue University’s Young Institute is tackling pharma’s toughest challenges— from mRNA stability to aseptic manufacturing.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.